Bioresorbable Coronary Stents Market Size & Growth Forecast 2027–2036, By Segments (Material, End Use, Drug), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Bioresorbable Coronary Stents Market size was estimated at USD 179 million in 2026 and is projected to grow at a 3.9% CAGR from 2027 to 2036, reaching USD 262.43 million by 2036. The industry revenue for 2027 is calculated at USD 184.87 million.
Get more details on this report
Request Free Sample ReportBioresorbable Coronary Stents Market Intelligence Snapshot
Regional Market Dynamics
- North America leads due to established interventional cardiology infrastructure, high coronary procedure volumes, and strong cath lab adoption supported by reimbursement and specialist availability.
- Asia Pacific growth at 17.14% CAGR is driven by expanding minimally invasive cardiac procedures, improving healthcare access, and growing catheterization lab capacity across hospitals and cardiac centers.
Segment Momentum
- Polymer-based stents held a 52.71% share in 2026 because they closely support the goal of temporary vessel scaffolding followed by gradual absorption, while benefiting from established clinical adoption and device development familiarity.
- Outpatient facilities accounted for 60.04% of the market and are the fastest-growing end-use segment due to efficient patient throughput, shorter stays, scheduling flexibility, and increasing focus on cost-effective cardiovascular procedures.
Market Expansion Drivers
- Rising cardiovascular disease prevalence increasing demand for advanced minimally invasive coronary interventions.
- Advancements in biocompatible polymer materials improving safety and performance of bioresorbable stents.
- Growing physician interest in temporary vascular scaffolding supporting next-generation coronary treatment adoption.
Leading Market Participants
- Key players in the bioresorbable coronary stents market include Abbott Laboratories (United States), BIOTRONIK SE & Co. KG (Germany), Meril Life Sciences Pvt. Ltd. (India), Elixir Medical Corporation (United States), REVA Medical, LLC (United States), MicroPort Scientific Corporation (China), Lepu Medical Technology Co., Ltd. (China), LifeTech Scientific Corporation (China), Arterial Remodeling Technologies SA (France), Kyoto Medical Planning Co., Ltd. (Japan).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 179 million
- 2027 Estimated Market Size: USD 184.87 million.
- Projected Market Size: USD 262.43 million by 2036
- Growth Forecast: 3.9% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Polymer (Material) | Outpatient Facilities (End Use) | Sirolimus (Drug)
- Emerging Opportunity Segment: Metal (Material) | Outpatient Facilities (End Use) | Novalimus (Drug)
Market Growth Drivers and Industry Trends
Rising cardiovascular disease prevalence increasing demand for advanced minimally invasive coronary interventions
The continuing burden of cardiovascular disease is increasing the need for coronary interventions, creating opportunities for advanced minimally invasive treatment approaches within the bioresorbable coronary stents market. Patients with obstructive coronary artery disease may require procedures to restore blood flow and improve vessel function, while advances in interventional cardiology are supporting less invasive treatment pathways. Bioresorbable stents are designed to provide temporary vascular support and subsequently degrade after fulfilling their structural role, distinguishing them from permanent metallic implants. This temporary approach is attracting attention in coronary treatment research as clinicians seek solutions that can reduce the long-term presence of implanted scaffolding within blood vessels.
Advancements in biocompatible polymer materials improving safety and performance of bioresorbable stents
Progress in polymer science and biocompatible material engineering is strengthening the bioresorbable coronary stents market by improving the characteristics required for temporary vascular scaffolding. Material selection directly influences properties such as mechanical strength, degradation behavior, biocompatibility, and drug-delivery performance, making continued development important for the clinical suitability of bioresorbable devices. Improvements in polymer composition and processing can help address challenges associated with maintaining adequate vessel support while enabling controlled material degradation. Researchers and manufacturers are therefore focusing on material systems that provide predictable performance within the vascular environment while minimizing adverse biological responses.
Growing physician interest in temporary vascular scaffolding supporting next-generation coronary treatment adoption
Increasing physician interest in treatment approaches that provide temporary rather than permanent vascular support is supporting innovation within the bioresorbable coronary stents market. Temporary scaffolding is intended to assist the treated vessel during the healing period before gradually resorbing, potentially reducing the long-term physical presence of an implant. This concept is particularly relevant to clinicians evaluating next-generation coronary intervention strategies that seek to balance immediate vessel support with longer-term vascular considerations. Ongoing improvements in stent architecture, delivery systems, polymer properties, and procedural techniques are helping physicians assess the suitability of bioresorbable technologies for different coronary anatomies and patient requirements.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising cardiovascular disease prevalence increasing demand for advanced minimally invasive coronary interventions | 1.90% | High | North America, Europe | High | Near Term |
| Advancements in biocompatible polymer materials improving safety and performance of bioresorbable stents | 1.60% | High | Europe, Asia Pacific | Emerging | Mid Term |
| Growing physician interest in temporary vascular scaffolding supporting next-generation coronary treatment adoption | 1.30% | Moderate | North America, Asia Pacific | Emerging | Long Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
The bioresorbable coronary stents market was dominated by North America in 2026, reflecting the region's advanced cardiovascular care infrastructure, high adoption of innovative interventional technologies, and strong clinical focus on improving long-term outcomes following coronary procedures. Established healthcare systems and extensive access to specialized cardiology services support the evaluation and adoption of emerging stent technologies. Continued attention to reducing the long-term presence of implanted devices, improving vascular healing, and addressing limitations associated with permanent metallic scaffolds is also sustaining interest in bioresorbable solutions. Research-oriented clinical environments and well-developed regulatory and reimbursement frameworks further contribute to the region's leading position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing region, supported by expanding cardiovascular care capacity, improving access to interventional cardiology, and increasing investment in advanced medical technologies. The growing burden of cardiovascular disease is encouraging healthcare providers to strengthen diagnostic and treatment infrastructure, while improvements in specialized cardiac centers are creating greater opportunities for innovative coronary interventions. Rising healthcare expenditure, increasing clinician familiarity with advanced stent technologies, and broader efforts to modernize medical facilities are also supporting market development. As healthcare systems increasingly pursue less invasive approaches and improved post-procedure outcomes, demand for next-generation coronary devices is expected to gain further momentum across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Clinical Evidence FocusGermany places strong emphasis on clinical validation and physician confidence when introducing bioresorbable coronary stents into cardiovascular practice. Hospitals in Germany increasingly assess long-term safety and procedural outcomes before expanding routine adoption.
France 🇫🇷
Evidence-Based Device AdoptionFrance prioritizes careful clinical assessment of bioresorbable coronary stents before wider procedural integration. Cardiovascular specialists in France increasingly focus on patient selection, procedural optimization, and long-term clinical performance when evaluating these devices.
Italy 🇮🇹
Interventional Care ModernizationItaly is incorporating bioresorbable coronary stents into evolving interventional cardiology practices where suitable patient profiles are identified. Healthcare providers in Italy continue strengthening clinical expertise and procedural consistency to support responsible technology adoption.
Japan 🇯🇵
Minimally Invasive AdvancementJapan supports bioresorbable coronary stent adoption through continued interest in minimally invasive cardiovascular treatment and improved patient outcomes. Medical institutions in Japan are evaluating devices that align with evolving interventional cardiology practices and evidence-based care.
South Korea 🇰🇷
Technology Evaluation PipelineSouth Korea is strengthening the evaluation of bioresorbable coronary stents through active collaboration between hospitals, clinicians, and device developers. Healthcare providers in South Korea are exploring advanced scaffold technologies that complement modern coronary intervention strategies.
United States 🇺🇸
Advanced Interventional AdoptionThe U.S. bioresorbable coronary stents market is driven by clinical interest in next-generation cardiovascular devices that reduce long-term implant presence. Healthcare providers in the U.S. continue evaluating improved scaffold designs supported by expanding clinical evidence and physician training.
Segment Leadership and Growth Trends
Bioresorbable Coronary Stents Market Share (%), by Material, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportMaterial Segment Analysis: Polymer (Largest Segment) vs Metal (Fastest-Growing Segment)
The polymer segment led the bioresorbable coronary stents market, holding a 52.71% share in 2026. Polymer-based materials have maintained a strong position because they can be engineered to gradually degrade after fulfilling their intended role in vessel support, potentially reducing the long-term presence of an implanted device. Their established use in bioresorbable stent development and the ability to tailor material characteristics for controlled degradation are supporting continued adoption. Ongoing interest in minimizing permanent foreign material within coronary vessels is also sustaining research and clinical attention toward polymer-based platforms, particularly where developers seek a balance between mechanical performance and biological compatibility.
The metal segment is expected to register the fastest growth as technological development continues to improve the performance of bioresorbable metallic platforms. Metal-based materials can provide favorable mechanical characteristics for vascular scaffolding while being designed to gradually resorb under controlled conditions. Advances in material engineering, degradation control, and stent design are improving the potential of these systems for coronary interventions. Growing interest in combining temporary structural support with eventual material disappearance is further encouraging development in this segment, strengthening the role of metal-based bioresorbable technologies within the broader shift toward next-generation coronary devices.
End Use Segment Analysis: Outpatient Facilities (Largest & Fastest-Growing Segment)
Outpatient facilities accounted for a 60.04% share of the bioresorbable coronary stents market in 2026 and represented both the largest and fastest-growing end-use segment. The segment benefits from the broader shift toward less invasive cardiovascular procedures and healthcare delivery models that emphasize shorter stays, efficient patient management, and reduced procedural burden. Advances in interventional cardiology are enabling an increasing range of coronary procedures to be performed in outpatient-oriented settings, supporting demand for devices that can be incorporated into streamlined treatment pathways. Bioresorbable stents are particularly aligned with the long-term objective of reducing the presence of permanent implants following vascular healing, which can enhance their appeal within evolving interventional care strategies. Continued improvements in procedural techniques, patient selection, and facility capabilities are expected to reinforce the importance of outpatient facilities in this market.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Material | Polymer, Metal | Polymer | Metal |
| End Use | Inpatient Facilities, Outpatient Facilities | Outpatient Facilities | Outpatient Facilities |
| Drug | Sirolimus, Novalimus, Others | Sirolimus | Novalimus |
Competitive Landscape and Market Positioning
Top players in the bioresorbable coronary stents market:
1. Abbott Laboratories (United States)
2. BIOTRONIK SE & Co. KG (Germany)
3. Meril Life Sciences Pvt. Ltd. (India)
4. Elixir Medical Corporation (United States)
5. REVA Medical LLC (United States)
6. MicroPort Scientific Corporation (China)
7. Lepu Medical Technology Co. Ltd. (China)
8. LifeTech Scientific Corporation (China)
9. Arterial Remodeling Technologies SA (France)
10. Kyoto Medical Planning Co. Ltd. (Japan)
Innovation within the bioresorbable coronary stents market is being driven by advancements in biodegradable materials and next-generation cardiovascular treatment technologies. Manufacturers are focusing on improving stent flexibility, absorption rates, and long-term patient outcomes through intensive research activities and clinical evaluations. Rising demand for minimally invasive cardiac procedures is also encouraging the development of technologically advanced solutions tailored to evolving regulatory and healthcare requirements.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories (United States) | |||||||
| BIOTRONIK SE & Co. KG (Germany) | |||||||
| Meril Life Sciences Pvt. Ltd. (India) | |||||||
| Elixir Medical Corporation (United States) | |||||||
| REVA Medical LLC (United States) | |||||||
| MicroPort Scientific Corporation (China) | |||||||
| Lepu Medical Technology Co. Ltd. (China) | |||||||
| LifeTech Scientific Corporation (China) | |||||||
| Arterial Remodeling Technologies SA (France) | |||||||
| Kyoto Medical Planning Co. Ltd. (Japan). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Shanghai MicroPort Medical (Group) Co., Ltd. | Jul-24 | Shanghai MicroPort Medical (Group) Co., Ltd. received regulatory approval from China's National Medical Products Administration for its Firesorb fully bioresorbable cardiac stent. The system features a targeted single-sided drug coating designed to accelerate vessel endothelial healing and improve long-term clinical safety. |
| Biotronik | Feb-24 | Biotronik obtained CE Mark approval and executed the European market launch of its Freesolve resorbable magnesium scaffold. The innovative metallic bioresorbable system optimizes vessel patency and provides predictable resorption kinetics to mitigate long-term stent thrombosis risks. |
| Reva Medical, LLC | Aug-22 | Reva Medical, LLC secured a USD 45.0 million capital investment to fund the final clinical phase and commercialization pipelines of its bioresorbable coronary stent portfolio. The funding injection supports the company's competitive re-entry into the bioresorbable vascular scaffold marketplace. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Bioresorbable Coronary Stents Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Clinical Indication | Stable Coronary Artery Disease, Acute Coronary Syndrome, Chronic Total Occlusion, Other Coronary Lesions |
| Lesion Complexity | Simple Lesions, Moderate-Complexity Lesions, Complex Lesions |
| Procurement Channel | Direct Hospital Procurement, Group Purchasing Organizations, Medical Device Distributors |
Bioresorbable Coronary Stents Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Hospital Adoption Readiness Evaluation |
|
| Reimbursement Access and Coverage Benchmarking |
|
| Next-Generation Bioresorbable Technology Pipeline Assessment |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the bioresorbable coronary stents market?
How much is the bioresorbable coronary stents industry expected to grow by 2036?
How are evolving interventional cardiology preferences influencing adoption in the bioresorbable coronary stents market?
Why are advances in biocompatible polymers strengthening the commercial outlook for bioresorbable coronary stents?
Why are polymer-based stents the leading material segment in the bioresorbable coronary stents market?
Why are outpatient facilities driving growth in the bioresorbable coronary stents market?
Why does North America lead the bioresorbable coronary stents market?
What is driving the fastest growth in Asia Pacific for this market?
Who are the leading players in the bioresorbable coronary stents landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization